GICS Sector : Healthcare
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.It develops its products using its proprietary bacteriophage-based technology.The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Up 12.8% – Still a Buy?
Dec -04
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
Nov -18
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Nov -12
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
Nov -12
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
Nov -10
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?
Oct -23
Armata data support advancing AP-SA02 to Phase 3, says H.C. Wainwright
Oct -22
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
Oct -22
Armata Pharmaceuticals' Pathogen-specific Bacteriophage Therapeutics growth is driven by increasing antibiotic resistance, rising demand for targeted therapies, and growing awareness of phage therapy's potential to combat multi-drug resistant infections. Additionally, partnerships with leading research institutions and government agencies, as well as expanding product pipelines, contribute to the 10.5% growth rate.
A bacteriophage-based therapeutic candidate for the treatment of Pseudomonas aeruginosa infections
A bacteriophage-based therapeutic candidate for the treatment of Staphylococcus aureus infections
A bacteriophage-based therapeutic candidate for the treatment of Pseudomonas aeruginosa infections
A bacteriophage-based therapeutic candidate for the treatment of Escherichia coli infections
Armata Pharmaceuticals, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies in the market.
Armata Pharmaceuticals, Inc. has a low bargaining power of customers due to the lack of concentration of buyers in the market.
Armata Pharmaceuticals, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers in the market.
Armata Pharmaceuticals, Inc. has a high threat of new entrants due to the attractiveness of the market and the ease of entry.
Armata Pharmaceuticals, Inc. operates in a highly competitive market with many established players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 153.69% |
| Debt Cost | 3.95% |
| Equity Weight | -53.69% |
| Equity Cost | 8.10% |
| WACC | 1.72% |
| Leverage | -286.26% |
Value: 5.4
Growth: 9.8
Quality: 9.4
Yield: 0.0
Momentum: 5.0
Volatility: 5.0
1-Year Total Return ->
Value: 3.1
Growth: 7.2
Quality: 8.5
Yield: 0.0
Momentum: 7.0
Volatility: 4.3
1-Year Total Return ->
Value: 8.2
Growth: 5.6
Quality: 6.1
Yield: 0.0
Momentum: 9.0
Volatility: 0.7
1-Year Total Return ->
Value: 4.8
Growth: 5.8
Quality: 5.8
Yield: 0.0
Momentum: 10.0
Volatility: 1.3
1-Year Total Return ->
Value: 8.0
Growth: 4.6
Quality: 6.1
Yield: 0.0
Momentum: 8.0
Volatility: 0.0
1-Year Total Return ->
Value: 6.0
Growth: 2.4
Quality: 3.2
Yield: 0.0
Momentum: 10.0
Volatility: 2.3
1-Year Total Return ->